Research Analysts’ Weekly Ratings Changes for Carlsmed (CARL)

Several brokerages have updated their recommendations and price targets on shares of Carlsmed (NASDAQ: CARL) in the last few weeks:

  • 11/11/2026 – Carlsmed had its price target raised by Truist Financial from $20.00 to $23.00. They now have a “buy” rating on the stock.
  • 11/11/2026 – Carlsmed had its price target raised by BTIG Research from $24.00 to $26.00. They now have a “buy” rating on the stock.
  • 11/11/2026 – Carlsmed had its price target raised by Needham & Company LLC from $17.00 to $22.00. They now have a “buy” rating on the stock.
  • 11/4/2026 – Carlsmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/12/2026 – Carlsmed had its price target raised by BTIG Research from $23.00 to $24.00. They now have a “buy” rating on the stock.
  • 9/28/2026 – Carlsmed had its “buy” rating reaffirmed by BTIG Research. They now have a $23.00 price target on the stock.

Carlsmed Stock Performance

CARL traded up $0.72 during trading on Monday, hitting $17.84. 100,726 shares of the stock were exchanged, compared to its average volume of 135,421. The stock has a fifty day moving average price of $14.97 and a two-hundred day moving average price of $12.58. Carlsmed, Inc. has a 1-year low of $8.50 and a 1-year high of $19.15. The firm has a market capitalization of $489.02 million, a P/E ratio of -12.06 and a beta of 1.97. The company has a quick ratio of 5.62, a current ratio of 5.79 and a debt-to-equity ratio of 0.20.

Carlsmed (NASDAQ:CARL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The business had revenue of $21.55 million during the quarter. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. As a group, sell-side analysts predict that Carlsmed, Inc. will post -1.53 earnings per share for the current year.

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.

Read More

Receive News & Ratings for Carlsmed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed Inc and related companies with MarketBeat.com's FREE daily email newsletter.